HUTCHMED (China) Limited (AIM:HCM)
United Kingdom flag United Kingdom · Delayed Price · Currency is GBP · Price in GBX
221.00
-2.00 (-0.90%)
Nov 17, 2026, 8:37 AM GMT
← View all transcripts

Deutsche Bank Virtual Investor Conference

Nov 12, 2026

Summary

H1 2026 oncology revenue rose 23% YoY, with FY revenue guidance held at $330m-$450m. The GSK A830 deal and positive savolitinib and sovleplenib milestones underpin pipeline and commercial expansion plans.

Zafar Aziz
Head of DR Investor Relations Advisory, Deutsche Bank

Hello, and welcome to the 31st Deutsche Bank Depositary Receipts Virtual Investor Conference, dbVIC. My name is Zafar Aziz from the DR Investor Relations Advisory Team at Deutsche Bank. I am pleased to announce that our next presentation will be from HUTCHMED. Before handing over to the presenter, some points to note.

Please submit your questions in the questions box. Please note all of today's presentations are recorded and can be accessed via the Deutsche Bank website, adr.db.com. At this point, I am very pleased to welcome our speaker from HUTCHMED.

Emily Kwong
Head of Capital Markets and Investor Relations, HUTCHMED

Good morning, good afternoon, and good evening, everyone. My name is Emily Kwong. I head up the Capital Markets and Investor Relations in HUTCHMED. Please note our safe harbor statement and disclaimer. The performance and results of operation of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is not a guarantee of future results. I would like to start our presentation today by giving highlights of our financials in 2026 first half.

First of all, our oncology revenue was $162 million, including $121 million products revenue. This represents a 23% growth over the first half of 2025. I would like to highlight that ELUNATE and SULANDA, the products, have recorded over 40% growth respectively in first half 2026. Sales of ex-China demand of FRUZAQLA continues to grow well, achieving an overall 14% growth in in-market sales.

Our 2026 full year's revenue guidance remains in the range of $330 million-$450 million. On R&D, the expenses amounted to $79 million for the first half. It is due to high investments in our discovery capabilities, including our talents and AI. On the bottom line, we continue to be profitable with net income of $16 million.

It is important to note that in last year, we have included a $416 million Shanghai Pharma JV's divestment gain, and also the share of post-divestments. With these strong operating results in cash, we continue to have a very good cash reserve of $1.4 billion. In September, we have announced a very exciting agreement with GSK on licensing out the ex-China rights of one of our ATTC assets. It is called A830.

HUTCHMED is a pioneer in our industry to have built a highly differentiated first-in-class novel ATTC asset platform with meaningful combination potential with standard of care for earlier line of treatments in the market. This also serves to validate our ATTC platform by a reputable MNC. As for GSK, this transaction will expand their global oncology reach, as well as advances their next-generation R&D portfolio from ADC to ATTC.

A quick highlight of the key terms of the transaction. What is it about? Our A830 is a first-in-class asset, which is a KRAS EGFR antibody conjugate. We are licensing this asset, ex-China rights, to GSK. This is a co-development deal in which HUTCHMED will be responsible for the global phase I development, and GSK will take over the ex-China development post-phase I. The total deal size would be around $1.3 billion, including upfronts of $110 million.

Once commercialized, HUTCHMED will receive tiered royalties. By doing this deal, HUTCHMED can accelerate the global development of the asset and unlock multiple indication opportunities. In terms of the pipeline, we can show you a snapshot of what we have right now. We have four products already in the market, fruquintinib, savolitinib, surufatinib, and now fanregratinib.

One more is coming to the market in next few months, which is called sovleplenib, our first immunology product, and two more candidates are in phase III. That is a strong commercial base today and a clear line of new launches of products behind it. Now, let me walk you through some of the key products in details. Savolitinib, which is our key drugs. We have dual focuses here, maintaining leadership in China and expanding the global footprint.

In China, savolitinib has been on the market since 2021 for MET exon 14 and NSCLC. Last year, the savolitinib plus osimertinib, which is called TAGRISSO from AstraZeneca combination, was approved in second-line EGFR-mutated and NSCLC. This June, we added gastric cancer. Next, we are moving the savolitinib plus TAGRISSO combination into first line. We plan to submit China NDA for SANOVO by the end of this year. Globally, this study is called SAFFRON.

It is very positive on the clinical data front. On that basis, we have also filed NDAs in the U.S., Europe, and Japan, and we expect approval in the second half next year. If approved, savolitinib will become HUTCHMED's second global drug, and it is a big opportunity. Around 35% of the patients who progress on third-generation EGFR inhibitors have MET overexpression or amplification.

On economics, we partnered global rights with AstraZeneca back in 2011, and remains very attractive for us. We received a 30% royalty on China sales and 9%-13% on sales outside of China. Just two weeks ago, we have two savolitinib studies read out in ESMO in Spain this year, and the data were very impressive. The global SAFFRON study was selected for the presidential symposium, and the China SANOVO study was also presented as a proffered paper.

So let me quickly walk you through the data. SAFFRON is a study that compares savolitinib plus TAGRISSO with chemo, the standard of care. The combination improved overall survival by 4.9 months and reduced the risk of death by 32%. We believe this can become a very new standard of care. SANOVO in China compared the combination of savolitinib and TAGRISSO with TAGRISSO alone in first line.

It established a clinically statistical significance. It extended progression-free survival, PFS, by 11.1 months and reduced the risk of death by 52%. Now, I would like to introduce another exciting platform, which is invented by HUTCHMED. It is called ATTC. So what does ATTC stand for? It is called antibody-targeted therapy conjugate. Unlike traditional ADC, ATTC replaces its cytotoxin, the chemo payload, with our targeted small molecule payload.

This differentiated dual mechanism of action could decrease on-target and off-tumor toxicity. The antibody and the payload work in both killing the cancer pathway, so we can deliver stronger efficacy and better safety compared to ADC that we see a lot in the market. So far, we have two announced proprietary payloads. By pairing novel payloads, targeted payloads with antibodies, we are building a pipeline of precision medicines. The HMPL-A830 is not just a single asset.

We are also advancing programs targeting PI3K/PIKK pathways across HER2 and EGFR targets or the biomarkers, including HMPL-A251 and HMPL-A580. Talking about our first payload, PI3K/PIKK, it is trying to address the PAM pathway, which is the single most frequently altered pathway across all solid tumors. Many of you heard about HER2 and EGFR biomarker as well, but each of them is altered in only one single-digit percentage of solid tumors. PAM, by contrast, is altered in 38%-50%, according to published literature.

Why hasn't PAM pathway been successfully dropped in the past? Because of toxicity. With our ATTC approach, the antibody delivers the payload precisely to the tumor. That would improve safety and finally let us go after the huge opportunity. PAM plays a very dominant role in a lot of solid tumors. Another payload, let's look at it. It's called KRAS.

It's a key protein that drives cell growth. When mutated, it causes cells to divide uncontrollably, leading to tumor. In fact, KRAS mutations are found in about 30% of all human cancers, particularly in hard-to-treat solid tumors like colorectal, pancreatic, and lung cancers. These tumor types also frequently overexpress EGFR. With these two assets currently in global trials, HMPL-A830 also has entered global phase I dose escalation study this September, and more candidates behind.

Our pipeline is very well-positioned to deliver sustainable growth for years to come. Next, we will introduce sovleplenib. It's called SYK, our HMPL-523 program, which will be HUTCHMED's first hematology and autoimmune product. It has two indications. First, wAIHA. In our phase III study, sovleplenib achieved a 66% durable response rate versus 15% on placebo. Compared with emerging options, the drug shows very clear efficacy advantage, and only 16% needed rescue therapy versus 54% on placebo.

These patients have limited treatment options currently, and we don't see a new targeted therapy for this area in 30 years. Our China NDA now is also under priority review. Second, the indication is ITP. Sovleplenib achieved a 48% durable response rate, even though 75% of patients had already been treated with TPO or TPORA therapies. Unlike TPORAs, it carries no thrombotic warning on its label.

The ESLIM-01 study is also under priority review in China, and we expect approval early next year. Let's look at another pipeline we have. It's called HMPL-760. It's a highly potent, selective, and reversible BTK inhibitor. Currently, this is the only BTK inhibitor in late-stage clinical development targeting second-line DLBCL or all-comers. Our phase II study showed a very encouraging response rate, PFS, and safety profile.

Our phase III study, registrational study, in China is also actively ongoing, comparing HMPL-760 in combination with chemo against the placebo plus chemo. We expect to complete enrollment by the end of 2027. Moving to our commercial platform. In first half 2026, our fruquintinib, FRUZAQLA, where Takeda is responsible for ex-China sales, had significant 70% growth outside the U.S. Moreover, looking at Q2, the growth rate was also up 27%.

It is already launched in 41 markets, and we believe there remains significant opportunity to launch in more countries and secure reimbursement. Moving to China, ELUNATE achieved robust growth in a highly competitive market. In the first half, growth reached 41%. The latest inclusion into the National Reimbursement Drug List renewal provides continuous growth opportunities, with the inclusion of second-line endometrial cancer, EMC. The second-line RCC approval in May 2026 will present another opportunity to expand our market share.

Furthermore, based on IQVIA, ELUNATE continues to maintain its market leadership in third-line mCRC. Beyond FRUZAQLA and ELUNATE, we also saw strong performance from ORPATHYS, which is our savolitinib and SULANDA. For savolitinib, like we mentioned before, we got approval for third-line MET-amplified gastric cancer. in October, we presented our SAFFRON and SANOVO readouts at ESMO 2026. Both demonstrated a very positive clinical result and huge market potential.

For SULANDA, we delivered strong first-half growth, supported by the top-tier recommendation in the CSCO guidelines for NET. This growth also reflects our focused commercial strategy, targeting top-tier cities and leading hospitals. Looking to the future, sovleplenib, our SYK inhibitor, will expand our footprint into hematology and immunology. As a potential best-in-class medicine, it has the potential to transform the treatment paradigm for both ITP and wAIHA.

In China, there are approximately 360,000 ITP patients and current therapies, such as TPO, TPORAs, and steroids, and those are very limited options, and still leaving significant unmet medical needs. Additionally, while wAIHA is a relatively small indication, there remains a critical unmet medical need for novel therapies. Sovleplenib represents the first potential targeted therapy in this area in over 30 years, with the potential to significantly reduce blood transfusions for these patients.

Both indications, I must say, have also just received orphan drug status in the U.S., which is also very exciting news for us, and under priority review in China. We expect the drug to be approved before early next year. Our strategy. To briefly highlight our outlook. On the commercial side, we expect FRUZAQLA's sales momentum to continue by penetrating further in the international markets.

As we explained earlier, the drug has already entered into 41 markets, so we expect the uptick to continue. ORPATHYS savolitinib represents another significant growth opportunity, following positive results from the global SAFFRON phase III study. We are working with AstraZeneca right now to advance regulatory approvals in the U.S., Europe, and Japan. The positive SANOVO phase III study also supports the expansion of savolitinib plus TAGRISSO combination into first-line treatment in China, further broadening its commercial potential.

Thirdly, we're preparing the launch of our hematology and immunology portfolio very soon. Finally, our ATTC platform will provide a long-term value creation through innovative drugs and global partnerships. That ends the presentation I have for today. I'll open the floor to questions. I'm seeing one question right now. It says, "The savolitinib data were very impressive, especially the first-line China data from SANOVO study.

What is AstraZeneca planning to advance the first-line development outside of China? Do they have any plans?" That's actually a very good question. We actually see AstraZeneca also present in the ESMO study last week, a couple weeks back in Spain, and I think the result is the strong results from SAFFRON in second line globally and SANOVO in first line in China. According to AZ, they're very actively looking at the potential for global first-line development.

As you know, EGFR mutations are found in around 50% of the Asian population in NSCLC patients, so it's a very dominant biomarker, compared with around 20% outside of Asia. I think AZ is saying that a bridging study could be one possible path instead of doing probably a global full-blown study.

In our opinion, it is in AstraZeneca's interest to capture a low-hanging fruit from its existing Tagrisso's landmark sales of $7.3 billion, and it would actually extend and solidify its leading market position by the savolitinib and Tagrisso combo. A second question I see is, "The GSK deal really stood out. When will we see the data for A830, and when will the data be available for the other two ATTC assets, 251 and 580?" I think this is also a very good question.

We plan to present the preclinical data for A830 at a scientific conference later this year, because our program has just entered the global phase I study in September. For the other two assets, the global phase I studies are also progressing well. They are also in global phase I dose escalation stage, and we plan to share phase I data next year.

Let me see the other questions. "Are we expecting more BD deals?" This is also a very popular question after our ATTC deal with GSK. Currently, we have several negotiations and discussions around our ATTCs, not only those we have disclosed, but also some undisclosed asset, as we saw earlier in that page. So, in addition to ATTCs, we also have early-stage pipeline assets. However, I think BD is pretty dynamic. We do not know until we sign the deal, and we actually are very open-minded in talking to a number of MNCs, but we will make an announcement when that time comes.

The other question I see from the audience is, "Will we revise our financial guidance, and what about guidance for next year?" I guess on this question, I would answer it like this, because our oncology and immunology revenue guidance would remain unchanged at $330 million-$450 million.

Next year, we would expect to have more new marketed products, including our first immunology product, as I mentioned earlier, is called sovleplenib, which is expected to be approved in China in few months, and the savolitinib plus Tagrisso combo, which is also targeted for approval in China and the U.S. So, we have aspiration for those products to be commercialized, and we will provide next year's guidance at our annual results announcement. That is going to be around March, the timing. I am just trying to look at the questions now. I see a question on data.

From a physician's perspective, what is the most compelling takeaway from SAFFRON study?" I guess this is a very good question because our PI, Dr. Wu, who acts for our study, and also AstraZeneca primarily in the global studies, I think the data is very impressive. It is the first global phase III trial to demonstrate statistically significant PFS and OS benefits in MET-driven EGFR-mutated NSCLC after the osimertinib progression.

We see the reduction in risk of death, and also is a mOS of 17.8 months against 12.9 months, and it is the first statistically significant OS benefit in post-osimertinib MET-driven resistance. As compared to, for example, Johnson & Johnson MARIPOSA, and also HARMONi study by Summit Therapeutics Inc., those studies' OS have no significant OS endpoint.

For the mPFS, we demonstrated 7.6 months against 5.4 months, and the HR is a very impressive ratio at 0.55. So, estimated 36% remained progression-free at one year versus 10% with chemo. For those of us newer to the science, what makes our asset HMPL-A830 exciting? I think that's the compound that we just licensed out to GSK.

Because the KRAS pathway is very popular in oncology studies, and when it's conjugated to EGFR, it makes a lot of solid tumors being killed by both blocking the KRAS and EGFR pathway. In other words, we are making it very broadened to a lot of solid tumors, like pancreatic, colorectal, breast cancer, and so on.

This is exactly why the ATTC platform is very innovative compared to ADC, because we're actually targeting both pathways and chemo-free studies. So, a lot of people can benefit by the KRAS ATTC asset to be in combination with other assets, including chemo, IO, and maybe even ADC or bispecific studies. As a longer-term shareholder, which upcoming milestone would you be most excited about? I think this is probably our last question, looking at the time.

The upcoming milestones I would be most excited about would be the hematology and immunology product, because this is going to be our first product in this category in our portfolio. I am very confident that it would make a difference to our sales, because it is going to be approved soon in China, and with the orphan drug status, we can even open up more BD opportunities with multinational.

This is one of the key milestones that we'll be able to hit in the next few months. Other than that, we will have more sales milestone from fruquintinib as we enter more markets and open up more reimbursements, as well as the savolitinib. The savolitinib product is what we are proud of, because it's going to be combined with Tagrisso and going to extend into second-line treatments globally or in the U.S., as well as pushing to the first-line treatment in China.

So, these are the few upcoming milestones that I will be very excited about. Maybe I can take one last question. There's a question on AI, right? Where is AI starting to make a practical difference in your drug discovery platform? I think everyone is chasing on the AI race.

We are also actually relying a bit on the AI drug discovery, whether that's actually from our in-house and also partnering with outside AI companies to try to drive the discovery faster. Speed is not just the key equation. We also have to do a lot of precision medicine, especially HUTCHMED is very proud of doing a lot of precision medicine, and then we'll try to identify assets and pathway quicker in our ATTC platform and other early-stage candidates in our pipeline. I hope that answered your question. I'll hand the forum back to Deutsche Bank.